AbbVie Inc.

ABBV-N

NYSE:ABBV

93.04
2.15 (2.37%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
HOLD
HOLD
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2019
They have Humera which makes up 62% of their revenue. This is not up-coming in the business but it represents some patent risk as it comes off patent in 4 years in the US. There will be competition around the world before then but not significant. They have to back stop this with other offerings. It could be through a purchase of a pipeline or something else. As time goes on you are going to get less and less benefit from this drug as an investment.
HOLD
HOLD
February 28, 2019
It has been a tough pharma name. It is the only single digit P/E on the large pharma space. There is execution risk. Probably the dividend yield is safe. He would put a stop loss at the beneath the $78 level.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 28, 2019
It has been a tough pharma name. It is the only single digit P/E on the large pharma space. There is execution risk. Probably the dividend yield is safe. He would put a stop loss at the beneath the $78 level.
DON'T BUY
DON'T BUY
February 21, 2019
The valuation is low and dividend is high. It cold be a trap. They focus in Humara. There is pressure from competition. He wouldn't be buying here as it carries more risk than it looks like.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 21, 2019
The valuation is low and dividend is high. It cold be a trap. They focus in Humara. There is pressure from competition. He wouldn't be buying here as it carries more risk than it looks like.
PAST TOP PICK
PAST TOP PICK
February 4, 2019
(A Top Pick Mar 23/18, Down 16%) He thinks this is a really good sector. The seasonality doesn't come in for a while yet. There is a double bottom, which is positive. There are few sectors that look like they are in a secular bull market like this one.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 4, 2019
(A Top Pick Mar 23/18, Down 16%) He thinks this is a really good sector. The seasonality doesn't come in for a while yet. There is a double bottom, which is positive. There are few sectors that look like they are in a secular bull market like this one.
BUY
BUY
November 7, 2018
Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 7, 2018
Just reported earnings last week, beating the street by 6%. It's been sideways, but pays a 4.9% dividend that should grow. Trades at 10x forward earnings at a 11% growth rate. But the market isn't recognizing this now. It's a good healthcare name, and healthcare has been outperforming the S&P in the current late cycle. ABBV has beaten earnings many quarters in a row.
HOLD
HOLD
September 12, 2018

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 12, 2018

Likes it, even though flat this year. Pays a nice dividend of 4.1%, which is expected to grow. Likes the healthcare space. Hold on to it and collect the dividend.

WATCH
WATCH
August 21, 2018

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
August 21, 2018

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

BUY
BUY
July 5, 2018

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
July 5, 2018

Is the yield sustainable? They are one of the largest biotech companies out there. They have one primary drug called Humera. It is an $18 billion dollar drug. They made a number of acquisitions. He sees the dividend as sustainable. Good valuation.

BUY
BUY
June 22, 2018

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 22, 2018

Nice little pharmaceutical name. 23% EPS growth. Trading at a reasonable 12 multiple. At these levels is OK to accumulate.

DON'T BUY
DON'T BUY
April 24, 2018

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 24, 2018

A bad acquisition two years ago hit them badly after that new company suffered a negative drug trial. Then, the stock dropped and he sold. There's probably still value in this stock, but he'd rather buy something else.

TOP PICK
TOP PICK
April 12, 2018

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 12, 2018

A spin-off from Abbott Laboratories (ABT-N). Strong exposure to immunology and oncology medicines. Dividend Yield of 4.2%. The stock sold off because they had a setback on a cancer drugs, but it is overdone in his opinion. Great way to own a strong growing pharma company. (Analysts’ price target is $120.27)

TOP PICK
TOP PICK
March 23, 2018

He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 23, 2018

He holds this in a pure technical system portfolio. It was down 13% yesterday and they decided to step in. A lung cancer drug recently announced disappointing results. They see health care in a secular bull market. A hot pick today.

STRONG BUY
STRONG BUY
March 21, 2018

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 21, 2018

Really likes this. They put up a monster quarter earlier this year as well as surprise drug trials for dermatitis that came in strong. They've won some patents. It's a $20-billion cash cow that they're reinvesting, some in partnerships with companies like J&J. Everything is working for it.

COMMENT
COMMENT
September 19, 2017

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 19, 2017

(Market Call Minute.) A company that was spun off from Abbott Labs (ABT-N) 2 or 3 years ago. A great company, but 66% of their revenue comes from 1 drug, Humira, the best selling drug in the world.

BUY
BUY
September 14, 2017

You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
September 14, 2017

You absolutely have to hold on to it if you have a 2 year outlook. Humera is the largest selling drug in the world. They are forever in patent disputes. They have taken this cash cow and used the proceeds to reinvest in their pipeline. They have a great balance sheet and a great yield. We are seeing great results from their trials. It should have double digit growth and should be at 15 times. It should consolidate higher than where it is.

Showing 16 to 30 of 55 entries